#SFHS2611793VUpdated reimbursement prices for aflibercept medicines in France
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
This notice sets new French list prices for several aflibercept eye-injection products, including Eylea and multiple biosimilars, starting 15 May 2026. It changes the pre-tax and public prices for each listed pack, which mainly matters for pharmacies, hospitals, payers, and manufacturers that bill or reimburse these products.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Sets new prices for Eylea 114.3 mg/ml and Eylea 40 mg/ml from 15 May 2026.
- Sets a lower common price point for multiple aflibercept biosimilars, including Afiveg, Afqlir, Ahzantive, Baiama, Eydenzelt, Mynzepli, Pavblu, and Yesafili.
- Applies separate pre-tax and public prices to each listed pack, which affects billing and reimbursement calculations.
Obligations
What this law requires
Manufacturers and pricing stakeholders must apply the listed pre-tax and public prices for the named aflibercept pharmaceutical specialties starting on 15 May 2026.
BAYER HEALTHCARE must use the new list prices of EUR 341.91 PFHT and EUR 392.56 PPTTC for the two EYLEA 114.3 mg/ml presentations identified in the notice from 15 May 2026.
BAYER HEALTHCARE must use the new list prices of EUR 282.73 PFHT and EUR 324.92 PPTTC for the two EYLEA 40 mg/ml presentations identified in the notice from 15 May 2026.
BIOGARAN must apply the listed price of EUR 212.05 PFHT and EUR 247.76 PPTTC for the AFIVEG presentation from 15 May 2026.
SANDOZ must apply the listed price of EUR 212.05 PFHT and EUR 247.76 PPTTC for the AFQLIR presentation from 15 May 2026.